Atea Pharmaceuticals, Inc. Common Stock (AVIR) Stock Price

AVIRStock

$5.36+54.47%52W

Market Cap$429.90M

P/E—

PEG Ratio—

Div yield—

Beta0.40

AVIR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)3.34%

Price vs S&P 500 (4W)14.73%

VGM Score71.03

Book Value / Share (Quarterly)$2.92

P/TBV (Annual)0.37x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.85

Price vs S&P 500 (YTD)37.32%

Net Profit Margin (TTM)34.46%

EPS (TTM)$-2.12

10-Day Avg Trading Volume0.19M

EPS Excl Extra (TTM)$-2.12

EPS (Annual)$-2.00

ROI (Annual)-38.28%

Cash / Share (Quarterly)$3.20

ROA (Last FY)-36.15%

EBITD / Share (TTM)$-2.37

ROE (5Y Avg)-13.16%

Operating Margin (TTM)39.41%

Cash Flow / Share (Annual)$-1.69

P/B Ratio1.74x

P/B Ratio (Quarterly)1.83x

Net Income / Employee (Annual)$-3,054,500

EV / Revenue (TTM)0.93x

ROA (TTM)-51.49%

EV / EBITDA (TTM)10.67x

EPS Incl Extra (Annual)$-2.00

Current Ratio (Annual)7.82x

Quick Ratio (Quarterly)7.67x

3-Month Avg Trading Volume0.32M

52-Week Price Return54.47%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$6.97

P/S Ratio (Annual)1.15x

Asset Turnover (Annual)0.45x

52-Week High$6.45

EPS Excl Extra (Annual)$-2.00

26-Week Price Return15.27%

Quick Ratio (Annual)7.59x

13-Week Price Return13.32%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)7.89x

Enterprise Value$326.42M

Asset Turnover (TTM)0.42x

Book Value / Share Growth (5Y)-11.91%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)39.44%

Cash / Share (Annual)$3.86

3-Month Return Std Dev43.32%

Net Income / Employee (TTM)$-3,082,100

ROE (Last FY)-38.28%

EPS Basic Excl Extra (Annual)$-2.00

Receivables Turnover (TTM)85.42x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.12

ROI (TTM)-57.01%

P/S Ratio (TTM)1.15x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$7.69

Price vs S&P 500 (52W)35.91%

Year-to-Date Return50.14%

5-Day Price Return-2.72%

EPS Normalized (Annual)$-2.00

ROA (5Y Avg)-12.39%

Net Profit Margin (Annual)34.49%

Month-to-Date Return14.04%

Cash Flow / Share (TTM)$-1.57

EBITD / Share (Annual)$-2.29

Operating Margin (Annual)39.39%

ROI (5Y Avg)-13.16%

EPS Basic Excl Extra (TTM)$-2.12

P/TBV (Quarterly)0.41x

P/B Ratio (Annual)1.01x

Pretax Margin (TTM)39.41%

Book Value / Share (Annual)$3.53

Price vs S&P 500 (13W)11.36%

Beta0.40x

P/FCF (Annual)1.37x

Revenue / Share (TTM)$0.00

ROE (TTM)-57.01%

52-Week Low$2.78

vGradeB

mGradeB

vgmGradeB

AVIR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$0.56	-$0.41	+26.13%(+$0.15)
Q4 2025	Mar 5, 2026	-$0.48	-$0.57	-17.53%(-$0.08)
Q3 2025	Nov 12, 2025	-$0.41	-$0.53	-27.71%(-$0.12)
Q2 2025	Aug 7, 2025	-$0.41	-$0.44	-6.02%(-$0.03)

AVIR Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.11

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
AVIRAtea Pharmaceuticals, Inc. Common Stock	B	—	B	$5.36
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Atea Pharmaceuticals, Inc. Common Stock

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing antiviral therapies for serious viral infections. The company's lead candidate, bemnifosbuvir, is in development for COVID-19, and a combination of bemnifosbuvir and ruzasvir is being evaluated for Hepatitis C treatment.